# A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

> **NCT06456580** · PHASE3 · RECRUITING · sponsor: **Vor Biopharma** · enrollment: 180 (estimated)

## Conditions studied

- Generalized Myasthenia Gravis

## Interventions

- **BIOLOGICAL:** Telitacicept
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06456580
- **Lead sponsor:** Vor Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-17
- **Primary completion:** 2027-05
- **Final completion:** 2029-01
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06456580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06456580, "A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06456580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*